Skip to content

Study · Animal study (in vivo) · mouse · 2024

3 results

Behavioral and neuropathological features of Alzheimer's disease are attenuated in 5xFAD mice treated with intranasal GHK peptide.

Tucker M, Liao GY, Keely A, Park JY, Rosenfeld M, Wezeman J, Mangalindan R, Ratner D, Darvas M, Ladiges W

Aging pathobiology and therapeutics30 Sept 2024Cited by 5 (Europe PMC)

PMID40766919 (opens in a new tab)PMCIDPMC12323558 (opens in a new tab)DOI10.31491/apt.2024.09.148 (opens in a new tab)PepBankPUB-40766919
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In 5xFAD Alzheimer's disease model mice, intranasal GHK‑Cu delayed cognitive impairment.

    In plain wordsIn mice with Alzheimer's-like disease, GHK‑Cu given through the nose delayed memory and thinking problems.

    Peptide
    GHK-Cu
    Outcome
    DecreaseCognitive impairment
    Study

    mousen: not reported in source

    5xFAD transgenic mice
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    15 mg/kg, 3 times per week · intranasal · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Results showed that intranasal GHK-Cu treatment delayed cognitive impairment, reduced amyloid plaques, and lowered MCP1-mediated inflammation levels in the frontal cortex and hippocampus.
    1 context sentence
    Summary · context
    Male and female 5xFAD transgenic mice on the C57BL/6J background at 4 months of age were given 15 mg/kg GHK-Cu intranasally 3 times per week for 3 months until 7 months of age.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In 5xFAD Alzheimer's disease model mice, intranasal GHK‑Cu reduced amyloid plaques.

    In plain wordsIn mice with Alzheimer's-like disease, GHK‑Cu given through the nose reduced amyloid plaques in the brain.

    Peptide
    GHK-Cu
    Outcome
    DecreaseAmyloid plaques in frontal cortex and hippocampus
    Study

    mousen: not reported in source

    5xFAD transgenic mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    15 mg/kg, 3 times per week · intranasal · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Results showed that intranasal GHK-Cu treatment delayed cognitive impairment, reduced amyloid plaques, and lowered MCP1-mediated inflammation levels in the frontal cortex and hippocampus.
    1 context sentence
    Summary · context
    Male and female 5xFAD transgenic mice on the C57BL/6J background at 4 months of age were given 15 mg/kg GHK-Cu intranasally 3 times per week for 3 months until 7 months of age.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In 5xFAD Alzheimer's disease model mice, intranasal GHK‑Cu lowered MCP1-mediated inflammation in the frontal cortex and hippocampus.

    In plain wordsIn mice with Alzheimer's-like disease, GHK‑Cu given through the nose lowered brain inflammation linked to MCP1.

    Peptide
    GHK-Cu
    Outcome
    DecreaseMCP1-mediated inflammation in frontal cortex and hippocampus
    Study

    mousen: not reported in source

    5xFAD transgenic mice
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    15 mg/kg, 3 times per week · intranasal · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Results showed that intranasal GHK-Cu treatment delayed cognitive impairment, reduced amyloid plaques, and lowered MCP1-mediated inflammation levels in the frontal cortex and hippocampus.
    1 context sentence
    Summary · context
    Male and female 5xFAD transgenic mice on the C57BL/6J background at 4 months of age were given 15 mg/kg GHK-Cu intranasally 3 times per week for 3 months until 7 months of age.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.